Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Capital International Ltd. CA

Capital International Ltd. CA increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 11.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 110,571 shares of the pharmaceutical company's stock after acquiring an additional 10,966 shares during the quarter. Vertex Pharmaceuticals comprises approximately 1.8% of Capital International Ltd. CA's holdings, making the stock its 9th largest holding. Capital International Ltd. CA's holdings in Vertex Pharmaceuticals were worth $44,527,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of VRTX. Norges Bank acquired a new position in Vertex Pharmaceuticals in the fourth quarter worth about $1,374,948,000. Parnassus Investments LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $731,283,000. Edgewood Management LLC boosted its stake in Vertex Pharmaceuticals by 91.2% in the 4th quarter. Edgewood Management LLC now owns 2,956,608 shares of the pharmaceutical company's stock valued at $1,190,626,000 after buying an additional 1,410,238 shares in the last quarter. Wellington Management Group LLP grew its position in Vertex Pharmaceuticals by 23.3% in the fourth quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company's stock valued at $2,382,407,000 after acquiring an additional 1,117,214 shares during the period. Finally, WCM Investment Management LLC bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at $435,899,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Up 0.3 %

Shares of NASDAQ:VRTX traded up $1.30 during trading on Wednesday, hitting $491.77. 455,276 shares of the company's stock traded hands, compared to its average volume of 1,325,321. The company has a 50-day moving average price of $487.81 and a 200-day moving average price of $465.64. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The company has a market cap of $126.28 billion, a price-to-earnings ratio of -223.53, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now owns 26,512 shares of the company's stock, valued at $13,256,000. This represents a 10.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the sale, the executive vice president now owns 67,695 shares in the company, valued at $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,315 shares of company stock valued at $2,121,012. Company insiders own 0.20% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Truist Financial lifted their price target on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Royal Bank of Canada lifted their price objective on Vertex Pharmaceuticals from $408.00 to $420.00 and gave the company a "sector perform" rating in a research report on Tuesday, April 1st. Scotiabank raised their target price on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the company a "sector perform" rating in a research note on Tuesday, February 11th. Barclays increased their price objective on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 11th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $535.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday. Ten research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $514.91.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.